People taking a cholesterol drug called evolocumab had almost twice as many heart failure deaths as those on a dummy pill in one big study, but this wasn’t mentioned in the main report—so scientists...
Strongly supported
Multiple high-quality studies back this claim.
Not medical advice. For informational purposes only. Always consult a healthcare professional.
People taking a cholesterol drug called evolocumab had almost twice as many heart failure deaths as those on a dummy pill in one big study, but this wasn’t mentioned in the main report—so scientists...
See the technical phrasing
In the FOURIER trial, the incidence of deaths due to cardiac failure was nearly twice as high in participants receiving evolocumab compared to those receiving placebo, a finding not reported in the original 2017 NEJM publication, suggesting a potential specific adverse cardiac effect associated with PCSK9 inhibition.
What the research says
Supports
1 study
Study: Restoring mortality data in the FOURIER cardiovascular outcomes trial of evolocumab in patients with cardiovascular disease: a reanalysis based on regulatory data
This study provides evidence supporting the claim.
Contradicts
0 studies
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies